Current methods of the modeling of experimental diabetes mellitus type 2: a literature review

Zaporizhzhia State Medical University

Key words: Diabetes Mellitus Type 2, Experimentation Animal, Insulin Resistance.

Background. Diabetes mellitus (DM) became a major problem of the healthcare in Ukraine. The rapid increase in the incidence was noticed especially in recent decade. The treatment of diabetes and its complications become a difficult task. From this standpoint the experimental modeling of diabetes is rather essential. Using the experimental models gives the possibility to assess the significance of the activity of pharmacological substances or to find out new mechanism in the action of medicaments.

The aim of this review is to light up the most studied and common experimental models of diabetes mellitus type 2 (T2DM) in small rodents and find out their drawbacks. It is known the background of T2DM is the violation of the insulin homeostasis such as the resistance of peripheral tissues to insulin as well as the dysfunction of the pancreatic beta-cells, which both lead to appearance of such phenomena as the glucosetoxicity and the lipotoxicity. In the end they both could result in life threatening vascular complications. Considering the steady growth of T2DM patients, the development both of the drug and non-drug methods of its treatment with the small rodents and

Conclusions. We should underline the adequate modeling of DM2T is the necessary basis for the pre-clinical study of drug-based and not-drug methods of correction of the hyperglycemic states. Using different models makes it possible for infer the obtained experimental results to the society, which suffers from DM2T.
Tracking the number of diabetes patients in 2000 was 175.4 million, and in 2015
the moderate hyperglycemia without significant changes in body weight or insulin levels, which are inherent for T2DM. Thus, in current models the partial pancreatectomy is usually combined with infusion of chemical diabetogenic substance (such as aloxan, streptozotocin and others). Furthermore, the pancreas has abilities for proliferation and regeneration, so these models are usually used during the transplantational studies [3].

Resent years a lot of experimental T2DM models were improved. They could be classified for 2 types: 1) genetical or spontaneous models and 2) non-genetical or induced. The interesting example of the genetically determined form of the insulin-independent form of DM is the diabetes in obese C57BL/KsJ-db/db mice. In homozigot state of this gene the obesity occurs. DM in this case is characterized with hyperphagia, polydipsia, polyuria, hyperglycemia, transient hyperinsulinemia and progressive insulin resistant. Drawbacks of this model are the increasing hyperglycemia and significant necrosis of beta cells in the age of 5–8 months. During several weeks the body weight decreases and rodent dies. It depends on beta cell destruction and insufficiency of their proliferation. These facts evidence about diabetes mellitus type 1–like state development [4].

It should be mentioned the genetic models are rather expensive. In this case the most popular are non-genetic models due to their simplicity, low cost and significance of the results [5,6]. In the last decade the models with the induction of the DM2T-like state in adult rodents using chemical substances with diabetogenic cytotoxic action such as streptozotocin (STZ), dexametasona, dithizone or using the violation of character of feeding (for example, treating rodents with high-fat diets) were proposed. Also the combinations of methods listed above were proposed: neonathal STZ models; STZ models with simultaneous or prior administration of nicotinamide; STZ models on the background of a high-fat diet and others. Let’s consider some of them. The STZ neonatal models are usually carried out on Wistar rats using one of the protocols of STZ administration: 1) a single intraperitoneal injection of STZ in dose of 100 mg/kg of animal weight on the second day after delivery; 2) a single intraperitoneal injection of STZ in dose of 80 mg/kg of animal weight on the 5th day of life. STZ should be diluted in citrate buffer (pH=4.5), and control group should receive the equivalent amount of the diluter. On 28th day after delivery rats should be taken out of mothers. In should be considered using 2nd protocol it is typical to get a significant amount of lethal cases (app. 50%) during of the first 3 days after STZ administration. In 1st type of STZ administration protocol in rats the acute insulin deficiency diabetes mellitus
occurs (significant hyperglycemia, hypoinsulinemia and decrease of the insulin amount in the pancreas with high glucagon levels in plasma with its normal amount in the pancreas). The mortality of this method is near 30%. The spontaneous remission was marked in several weeks. It was accompanied with the beta cells regeneration and the glucose and insulin levels in plasma restore to normal conditions. The moderate basal hyperglycemia accompanied with impaired glucose tolerance appears from 8-week age of rodents. The pancreatic insulin level usually decreased approximately by 50% without glucagon amount changed. In addition, the glucose induced insulin secretion is significantly decreased in these animals with normal effect of the non-glucose pancreatic secretogens.

Using the 2nd type of protocol more severe form of diabetes occurs. After the relatively short period of the acute insulin deficiency syndrome the significant basal hyperglycemia with impaired glucose tolerance, high levels of glycosylated hemoglobin, significant decrease of insulin levels with the insulin resistance are usually observed. Beginning of the hyperglycemia and decrease of the insulin response to increased glucose plasma levels are observed already during 4th week. It should be mentioned the significance of insulin-independent component during this model in adult rats after neonatal STZ injection also depends on the rats’ breed line and diet type. Thus, the degree of diabetes-like metabolic changes in female Sprague-Dawley rats after the diabetes induction on the 2nd day with STZ dose of 80 mg/kg was equal to 5th day and 90 mg/kg STZ effect in Wistar rats. Additionally, a high-fat diet worsens the glucose homeostasis’s state in this model.

In conditions of this model of the neonatal STZ insulin-independent diabetes mellitus the specific insufficiency of the glucose insulin response with the normal insulin response for other secretogenes observed. Such violations of beta cells reaction are typical for DM2T. Thus this model could be used for assessment of glucose lowering action of biologically active substances in case of their long-term usage [7].

It seems to be interesting the model of experimental DM2T based on a partial affection of the beta cells in result of repeated administration of low doses of STZ to adult rats [8]. Diabetes is induced by the everyday intraperitoneal administration of ex tempore solution of STZ (15 mg/kg of STZ in 1mM citrate buffer, pH=4.5) during 5 days to mature Wistar male rats with 280–300 g weight. Animals starve with free access to water during 16 hours prior to STZ injection. For the following experiments the rats with glycemia level above 7–8 mmole/l and below 11.1 mmole/l are usually taken. This DM2T model is characterized with partial insulin deficiency with following hyperglycemia but without violation of peripheral insulin resistance [9].

STZ induced diabetes with simultaneous injection of nicotinamide allows to partially protect the beta cells against cytoxic action of this diabetogenic substance. Rats in 3-month age are treated with nicotinamide intraperitonealy in dose of 230 mg/kg 15 minutes prior to the intraperitoneal injection of 65 mg/kg of STZ. It results in moderate and stable basal hyperglycemia with approximately 40% of pancreatic insulin saved. This model is characterized with carbohydrate intolerance and relative insufficiency of the insulin secretion in response to the hyperglycemia, which are combined with preserved secretory response to non-glucose stimuli and secondary insulin resistance development. Thus, this model allows producing the main signs of DM2T in human: they are the insulin secretion and action violations. This allows using this model in the assessment of the hypoglycemic effects of new biologically active substances with different mechanisms of action.

In several cases of preclinical studies of new anti-diabetic drugs, the dexamethasone model of insulin-independent diabetes is used. It is known the high doses of glucocorticoids could produce the violation of secretory activity of beta cells and insulin resistance development. One of the protocols of such models is described below.

This model is reproduced by following actions: Wistar rats in age of 18 months are treated with subcutaneous injections of dexamethasone solution in dose of 0.125 mg/kg of rats’ body weight. During the experiment there were observed the moderate basal hyperglycemia, twofold increase in the insulin and the unsaturated fatty acids plasma levels, impaired glucose tolerance and low sensitivity of peripheral tissues to insulin [19]. Later it was shown the decrease of glucose consumption by adipocytes after the dexamethasone treatment is accompanied by its direct action to the GLUT1 and GLUT4 expression, which leads to insulin resistance development [11]. The suppressing effect of dexamethasone on the secretory activity of beta cells is trusted to be mediated by inactivation of mitochondrial FAD-glycerophosphate dehydrogenase, which is a key enzyme in glucose-induced insulin secretion [12].

Thus, the dexamethasone DM2T model in mature rats allows causing the violations of insulin’s secretion and activity, like the nicotinamide/STZ model. In the same time there is another method of dexamethasone administration, namely its injection using the same protocol but in 3-month Wistar rats, which leads to impaired glucose tolerance, insulin resistance, hyperinsulinemia, but not to basal hyperglycemia. Using this method, we can reproduce the pre-diabetes state. It allows us to assess new hypoglycemic substances and study the mechanisms of their action and their influence on the prevention of diabetes development, which could be connected with the improvement of glucose tolerance or with the increase in insulin sensitivity of peripheral tissues.

Recently many researchers reported the treating of rats with a diet with high fat contain could lead to the insulin resistance development [13–15]. Considering the fact that low doses of STZ provoke moderate impairment of insulin secretion, like in late phase of DM2T [16–17], some models were developed, which actually are the combinations of the high-fat diet and the low STZ doses administration. These models appear to be very interesting for pharmacology due to their ability to reproduce the metabolic peculiarities of DM2T, which are typical for humans [17–18]. We describe one of such models below.
Sprague-Dawley rats with body weight of 160–180 g were on high-fat diet (58% of calories due to fat) during 2 weeks. The control group received common commercial type of food (12% of calories due to fat). In rats of the experimental group it was found the significant increase of the body weight, the glucose basal plasma level, insulin, triglycerides and general cholesterol compared with the control group. Hyperinsulinemia with significant decrease of glucose consumption according to results of the intravenous glucose tolerance test proved the occurrence of insulin resistance. After 2 weeks of high-fat diet in both groups STZ in low dose (35 mg/kg) was injected. In rats of experimental group, the significant hyperglycemia was observed according to STZ injection response. Control group showed the moderate increase of glucose plasma level. The insulin plasma level in rats of the experimental group was lowered to the level of control rats after STZ injection. In addition, in rats of experimental group the triglycerides and cholesterol plasma levels remained elevated. Vice versa, in rats of control group, which were on diet with the normal contain of fats, STZ caused no significant changes in plasma levels of insulin, triglycerides and general cholesterol. Thus, authors concluded this model (of high-fat diet and STZ combination) reproduces the natural pathway of DM2T development with its metabolic features typical to persons with the high risk of DM2T development due to insulin resistance and obesity presence and, thereby, could be used as a DM2T experimental model. Zhang M. et al. in 2008 proposed a stable model of DM2T in Wistar rats (200–250g) using the combination of high-fat diet (4 weeks) and twofold injection of low doses of STZ intraperitoneally (30 mg/kg of body weight) with an interval of 2 weeks [19].

It should be noted that the data mentioned above do not reflect the whole spectrum of the developed DM2T models. Their number is growing, but they are not sufficiently studied. It also should be considered, that each experimental model reproduces only certain pathways of the DM2T pathogenesis and has not got the full compliance with the human’s disease development and progress. Therefore, there are a lot of activities all around the world, which are focused on the modification of existing models and creation of new sophisticated models of DM2T which would have the best reflect of metabolic changes typical for human’s DM2T.

**Conclusions.** Considering mentioned above, we should underline the adequate modelling of DM2T is the necessary basis for the pre-clinical study of drug-based and non-drug methods of correction of the hyperglycemic states. Using different models make it possible for infer the obtained experimental results to the society, which suffers from DM2T.

**Conflicts of Interest:** authors have no conflict of interest to declare.

---

**References**


**Information about authors:**
Kolesnyk Yu. M., MD, PhD, DSci, Professor, Rector of Zaporozhzhia State Medical University, Head of the Department of Pathological Physiology of Zaporozhzhia State Medical University.

Ivanenko T. V., MD, PhD, Senior Lecturer of the Department of Pathological Physiology of Zaporozhzhia State Medical University, E-mail: ivanenko@zsmu.pp.ua.

Abramov A. V., MD, PhD, DSci, Professor of the Department of Pathological Physiology of Zaporozhzhia State Medical University.

Kuzo N. V., MD, Lecturer-Intern of the Department of Pathological Physiology of Zaporozhzhia State Medical University.

**Відомості про авторів:**
Колесник Ю. М., д-р мед. наук, професор, зав. каф. патологічної фізіології, ректор Запорізького державного медичного університету.

Іваненко Т. В., старший викладач каф. патологічної фізіології, Запорізький державний медичний університет, E-mail: ivanenko@zsmu.pp.ua.

Абрамов А. В., д-р мед. наук, професор каф. патологічної фізіології, Запорізький державний медичний університет.

Кузьо Н. В., викладач-стажист каф. патологічної фізіології, Запорізький державний медичний університет.

**Сведения об авторах:**
Колесник Ю. М., д-р мед. наук, професор, зав. каф. патологической физиологии, ректор Запорожского государственного медицинского университета.

Иваненко Т. В., старший преподаватель каф. патологической физиологии, Запорожский государственный медицинский университет, E-mail: ivanenko@zsmu.pp.ua.

Абрамов А. В., д-р мед. наук, профессор каф. патологической физиологии, Запорожский государственный медицинский университет.

Кузьо Н. В., преподаватель-стажист каф. патологической физиологии, Запорожский государственный медицинский университет.

Надійшла в редакцію 12.04.2016 р.